Rationalizing the Use of Pembrolizumab/Bevacizumab in Women With Recurrent Ovarian Cancer

Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center explains the rationale for the a phase II study, which combined pembrolizumab with bevacizumab in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the SGO Annual Meeting.

Emese Zsiros, MD, PhD, FACOG, assistant professor of oncology, Department of Gynecologic Oncology, Center for Immunotherapy, Roswell Park Comprehensive Cancer Center, explains the rationale for the a phase II study, which combined pembrolizumab (Keytruda) with bevacizumab (Avastin) in patients with recurrent ovarian cancer. Zsiros presented data on the study in early 2019 at the Society of Gynecologic Oncology (SGO) Annual Meeting.

The rationale for the phase II open-label study of pembrolizumab plus bevacizumab versus pembrolizumab alone was to understand whether the efficacy seen with single-agent pembrolizumab can be enhanced with the addition of bevacizumab, an anti-angiogenic agent and an oral cyclophosphamide.